Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.56 |
| ▸ | IL2 | P60568 | 2/20 | 0.55 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.50 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.47 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.44 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.44 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.44 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.44 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5049887 | 0.83 | IL2 (0.70) | HDAC6IL2DGAT1NPY5RKCNQ3 | |
| SCHEMBL5049062 | 0.81 | IL2 (0.51) | HDAC6IL2NPY5RHDAC1ALDH1A1 | |
| SCHEMBL14364255 | 0.81 | NPY5R (0.50) | IL2NPY5RALDH1A1RORBNTRK1 | |
| SCHEMBL5051437 | 0.80 | IL2 (0.66) | HDAC6IL2KCNQ3KCNQ2KCNE1 | |
| SCHEMBL5051391 | 0.79 | IL2 (0.49) | HDAC6IL2DGAT1HDAC1NTRK1 | |
| SCHEMBL8237254 | 0.77 | HSD17B1 (0.54) | HDAC6IL2DGAT1PIK3CDPIK3CA | |
| SCHEMBL594373 | 0.72 | KDR (0.50) | HDAC6IL2DGAT1ALDH1A1 | |
| SCHEMBL6248559 | 0.72 | KDR (0.71) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL20764014 | 0.71 | ESRRG (0.67) | — | |
| SCHEMBL5269083 | 0.71 | IL2 (1.00) | HDAC6IL2KIF11RORB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140135331-A9 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-05-15 | — | — | US | claimed |
| US-20130317032-A1 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-11-28 | — | — | US | claimed |
| EP-1983980-A2 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2008-10-29 | — | — | EP | claimed |
| US-20070254925-A1 | Thiazole and thiadiazole compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-01 | — | — | US | claimed |
| WO-2007087427-A2 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-02 | — | — | WO | claimed |
| US-20140135331-A9 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135331-A9 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20130317032-A1 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-11-28 | — | — | US | disclosed |
| US-8455658-B2 | Thiazole and thiadiazole compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455658-B2 | Thiazole and thiadiazole compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455658-B2 | Thiazole and thiadiazole compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| EP-1983980-A2 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20070254925-A1 | Thiazole and thiadiazole compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254925-A1 | Thiazole and thiadiazole compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254925-A1 | Thiazole and thiadiazole compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-01 | — | — | US | disclosed |
| WO-2007087427-A2 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130317032-A1 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCR1, NLRP3, NLRP1 | HDAC6 386/4885IL2 29/4885DGAT1 2315/4885 |
| US-20140135331-A9 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCR1, NLRP3, NLRP1 | HDAC6 386/4885IL2 29/4885DGAT1 2315/4885 |
| US-20070254925-A1 | Thiazole and thiadiazole compounds for inflammation and immune-related uses | CXCR1, NLRP3, NLRP1 | HDAC6 386/4885IL2 29/4885DGAT1 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.